ATE216883T1 - Verwendung von 4-phenyl-3,6-dihydro-2h-pyridyl derivaten als nmda rezeptor subtyp blocker - Google Patents

Verwendung von 4-phenyl-3,6-dihydro-2h-pyridyl derivaten als nmda rezeptor subtyp blocker

Info

Publication number
ATE216883T1
ATE216883T1 AT97905107T AT97905107T ATE216883T1 AT E216883 T1 ATE216883 T1 AT E216883T1 AT 97905107 T AT97905107 T AT 97905107T AT 97905107 T AT97905107 T AT 97905107T AT E216883 T1 ATE216883 T1 AT E216883T1
Authority
AT
Austria
Prior art keywords
nmda receptor
receptor subtype
hydrogen
dihydro
phenyl
Prior art date
Application number
AT97905107T
Other languages
English (en)
Inventor
Anne Bourson
Guenther Fischer
Neidhart Marie-Paule Heitz
Vincent Mutel
Gerhard Trube
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE216883T1 publication Critical patent/ATE216883T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT97905107T 1996-03-08 1997-02-27 Verwendung von 4-phenyl-3,6-dihydro-2h-pyridyl derivaten als nmda rezeptor subtyp blocker ATE216883T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96103636 1996-03-08
PCT/EP1997/000951 WO1997032581A1 (en) 1996-03-08 1997-02-27 Use of 4-phenyl-3,6-dihydro-2h-pyridyl derivatives as nmda receptor subtype blockers

Publications (1)

Publication Number Publication Date
ATE216883T1 true ATE216883T1 (de) 2002-05-15

Family

ID=8222541

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97905107T ATE216883T1 (de) 1996-03-08 1997-02-27 Verwendung von 4-phenyl-3,6-dihydro-2h-pyridyl derivaten als nmda rezeptor subtyp blocker

Country Status (15)

Country Link
US (1) US5962472A (de)
EP (1) EP0885004B1 (de)
JP (1) JP3248917B2 (de)
KR (1) KR100352358B1 (de)
CN (1) CN1131031C (de)
AT (1) ATE216883T1 (de)
AU (1) AU717140B2 (de)
BR (1) BR9708171A (de)
CA (1) CA2248134A1 (de)
DE (1) DE69712325T2 (de)
DK (1) DK0885004T3 (de)
ES (1) ES2174220T3 (de)
PT (1) PT885004E (de)
TR (1) TR199801774T2 (de)
WO (1) WO1997032581A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1674087A1 (de) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylaktische Verwendung von N-Methyl-D-Aspartat Rezeptor (NMDA) Antagonisten
WO2002072542A2 (en) * 2001-03-08 2002-09-19 Emory University Ph-dependent nmda receptor antagonists
US6951875B2 (en) * 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
US7671072B2 (en) * 2003-11-26 2010-03-02 Pfizer Inc. Aminopyrazole derivatives as GSK-3 inhibitors
CN103058957A (zh) 2007-06-29 2013-04-24 埃莫里大学 用于神经保护的nmda受体拮抗剂
MX2010009649A (es) * 2008-03-27 2010-12-17 Evotecv Neurosciences Gmbh Metodos para tratar trastornos utilizando un antagonista selectivo del subtipo nr2b de nmda.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH506525A (de) * 1968-12-24 1971-04-30 Hoffmann La Roche Verfahren zur Herstellung von aromatischen Äthern
CH558354A (de) * 1970-06-17 1975-01-31 Hoffmann La Roche Verfahren zur herstellung von aromatischen aethern.
CH547802A (de) * 1970-06-19 1974-04-11 Hoffmann La Roche Verfahren zur herstellung von tetrahydropyridinderivaten.
US3879405A (en) * 1970-06-19 1975-04-22 Hoffmann La Roche Tetrahydropyridine derivatives
US5149817A (en) * 1990-03-05 1992-09-22 Shionogi & Co., Ltd. Teirahydropyridine derivatives
DE4325885A1 (de) * 1993-08-02 1995-02-09 Basf Ag Elektrolumineszierende Anordnung
DE4325855A1 (de) 1993-08-02 1995-02-09 Boehringer Ingelheim Kg Neue Benzoesäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410822A1 (de) * 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
US5698565A (en) * 1995-06-09 1997-12-16 Hoffmann-La Roche Inc. Use of phenoxy-pyridine derivatives

Also Published As

Publication number Publication date
TR199801774T2 (xx) 1998-12-21
AU1878297A (en) 1997-09-22
PT885004E (pt) 2002-08-30
KR19990087505A (ko) 1999-12-27
JP2000507542A (ja) 2000-06-20
CN1213304A (zh) 1999-04-07
EP0885004A1 (de) 1998-12-23
WO1997032581A1 (en) 1997-09-12
CA2248134A1 (en) 1997-09-12
US5962472A (en) 1999-10-05
DK0885004T3 (da) 2002-08-19
AU717140B2 (en) 2000-03-16
DE69712325T2 (de) 2002-11-28
CN1131031C (zh) 2003-12-17
DE69712325D1 (de) 2002-06-06
BR9708171A (pt) 1999-07-27
ES2174220T3 (es) 2002-11-01
JP3248917B2 (ja) 2002-01-21
KR100352358B1 (ko) 2003-03-10
EP0885004B1 (de) 2002-05-02

Similar Documents

Publication Publication Date Title
EA200700232A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
DK0687268T3 (da) Spiroazacykliske derivater som substans P-antagonister
ATE139233T1 (de) Annelierte thiophen-derivate, ihre herstellung und verwendung
HUP0001192A2 (hu) Topiramát és származékainak alkalmazása elhízás kezelésére használható gyógyszerkészítmények előállítására
DK0533280T3 (da) Ny medicinsk anvendelse af tachykininantagonister
NO954694L (no) Doseringsform for antidepressiva
DE69523169D1 (de) Verwendung von Mangiferin oder seinen Derivaten zur kosmetischen Anwendung
DE69616480D1 (de) Piperidinderivate als neurokininantagonisten
DE69331190D1 (de) Überbrückte azabicyclische derivate als substanz p antagonisten
WO1993014084A3 (en) Piperidine derivatives
MY114425A (en) Quinazoline derivatives
TW336939B (en) Lipopeptide derivatives, a process for their preparation and their use
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
JO2321B1 (en) 4-phenyl-pyridine derivatives
WO1999024022A3 (en) Isoquinoline derivatives for treating disorders associated with 5ht7 receptors
IL119828A (en) 6-(disubstituted amino)-2,4-¬(bis(hydroxyaryl)¾-1,3,5-triazine derivatives their preparation and cosmetic light-screening agents containing them
DK0779284T3 (da) Hidtil ukendte 2-naphtanamidderivater og terapeutiske anvendelser heraf som agonister af D3-receptorer
NO20001514L (no) Vitronectin-reseptor-antagonist
DE69712325D1 (de) Verwendung von 4-phenyl-3,6-dihydro-2h-pyridyl derivaten als nmda rezeptor subtyp blocker
ATE121385T1 (de) Harnstoffderivate, ihre herstellung und ihre verwendung bei der therapie.
ATE169019T1 (de) Xanthinderivate als adenosin-a1 rezeptor antagonisten
NO973241L (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av hyperlipoproteinemi, hypertriglyceridemi, hyperlipidemi eller hyperkolesterolemi, eller arteriosklerose, eller for antikoagulativ b
NO20023041L (no) Fremgangsmåte for fremstilling av pyrazolopyridazinderivater
ES2162078T3 (es) Compuestos terapeuticos.
DE59904415D1 (de) Verwendung von Moxonidin als Thermogenese stimulierend wirksames Arzneimittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee